Other therapeutic strategies exploiting potential metabolic vulnerabilities in IDH1mut gliomas, including inhibitors of poly (ADP-ribose) polymerase and nicotinamide phosphoribosyltransferase, are also being pursued [29–31]. This evidence concerns the gene NAMPT and central nervous system cancer.